

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6970460

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CIT BANK, N.A.	10/12/2021
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	RVL PHARMACEUTICALS, INC.
<b>Street Address:</b>	400 CROSSING BOULEVARD
<b>City:</b>	BRIDGEWATER
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	08807
<b>PROPERTY NUMBERS Total: 8</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	62843819
Application Number:	62844069
Application Number:	16715998
Application Number:	16716014
Application Number:	17064915
Application Number:	17063416
Application Number:	17154676
Application Number:	17194559
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	jonathan.bradford@ropesgray.com
<b>Correspondent Name:</b>	ROPES & GRAY LLP
<b>Address Line 1:</b>	PRUDENTIAL TOWER
<b>Address Line 2:</b>	800 BOYLSTON STREET
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02199-3600
<b>ATTORNEY DOCKET NUMBER:</b>	104426-1000-016
<b>NAME OF SUBMITTER:</b>	JONATHAN BRADFORD
<b>SIGNATURE:</b>	/JONATHAN BRADFORD/

<b>DATE SIGNED:</b>	10/15/2021
---------------------	------------

**Total Attachments: 4**

source=CIT Osmotica - Payoff - RVL Pharmaceuticals Patent Release [EXECUTED]#page1.tif

source=CIT Osmotica - Payoff - RVL Pharmaceuticals Patent Release [EXECUTED]#page2.tif

source=CIT Osmotica - Payoff - RVL Pharmaceuticals Patent Release [EXECUTED]#page3.tif

source=CIT Osmotica - Payoff - RVL Pharmaceuticals Patent Release [EXECUTED]#page4.tif

RELEASE OF PATENT SECURITY AGREEMENTS

This Release of Patent Security Agreements (this “Release”) is made as of October 12, 2021, by CIT Bank, N.A. (the “Grantee”), having its principal offices at 11 West 42<sup>nd</sup> Street, New York, NY 10036, as collateral agent (the “Collateral Agent”), for the benefit of RVL PHARMACEUTICALS, INC., a Delaware corporation with principal offices at 400 Crossing Boulevard, Bridgewater, NJ 08807, (the “Grantor”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed thereto in the Security Agreement or Patent Security Agreements, as applicable.

WHEREAS, pursuant to that certain Pledge and Security Agreement, dated as of February 3, 2016 (as amended, modified, restated and/or supplemented from time to time, the “Security Agreement”) made by the Grantor, Collateral Agent, and others party thereto, and those certain Grants of Security Interest in United States Patents set forth on Schedule I hereto (collectively, the “Patent Security Agreements”) made by the Grantor and Collateral Agent, the Grantor assigned to the Collateral Agent as collateral security, and granted to the Collateral Agent, a continuing security interest in, to and under (i) the Patents (including the Patents set forth on Schedule II hereto); (ii) all Proceeds and products of the Patents; and (iii) all causes of action arising for infringement of any of the Patents or unfair competition regarding the same (collectively, the “Patent Collateral”), to secure payment, performance and observance of the obligations;

WHEREAS, the Patent Security Agreements were recorded in the United States Patent and Trademark Office as set forth on Schedule I; and

WHEREAS, the Grantor has requested that the Collateral Agent release, and the Collateral Agent is willing to release its security interest with respect to the Patent Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby agrees as follows:

1. The Collateral Agent hereby terminates the Patent Security Agreements and terminates, releases and discharges any and all security interests granted under the Security Agreement and Patent Security Agreements that it may have in, to, and under the Patent Collateral. Any right, title or interest of the Collateral Agent in such Patent Collateral shall hereby terminate, cease and become void. The Collateral Agent hereby assigns, transfers and conveys any and all right, title or interest of the Collateral Agent in such Patent Collateral to the Grantor.

2. The Collateral Agent hereby agrees to duly execute, acknowledge, procure and deliver any further documents and to do such other acts, at the Grantor’s sole cost and expense, as may be reasonably necessary to effect the release of the Patent Collateral contemplated hereby.


3. This Release may be executed in any number of counterparts (including electronic transmission and facsimile counterparts), each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument.

4. This Release and the rights and obligations of the parties hereunder shall be governed by, and shall be construed and enforced in accordance with, the laws of the State of New York.

[Remainder of this page intentionally left blank; signature page follows]

IN WITNESS WHEREOF, the undersigned has caused this Release of Patent Security Agreements to be executed and delivered as of the date first written above.

CIT Bank, N.A., as Collateral Agent

By:  \_\_\_\_\_

Name: John S. Yusi III

Title: Senior Vice President

## **SCHEDULE I**

### **Patent Security Agreements**

Grant of Security Interest in United States Patents dated May 21, 2020 recorded at the U.S. Patent and Trademark Office on May 22, 2020 at Reel/Frame 52734/0192

Grant of Security Interest in United States Patents dated January 22, 2021 recorded at the U.S. Patent and Trademark Office on January 25, 2021 at Reel/Frame 550125/0762

Grant of Security Interest in United States Patents dated June 30, 2021 recorded at the U.S. Patent and Trademark Office on June 30, 2021 at Reel/Frame 56724/0588

**SCHEDULE II**

**Patents**

Reel/Frame 52734/0192

Patent No. Publication Date Application No.	Issue Date Pub. Date App. Date	Title	Owner
62/843,819	5/6/19	COMPOSITIONS AND METHODS FOR TREATING BLEPHAROPTOSI	RVL PHARMACEUTICALS, INC.
62/844,069	5/6/19	COMPOSITIONS AND METHODS FOR TREATING BLEPHAROPTOSIS	RVL PHARMACEUTICALS, INC.
16/715,998	12/16/19	OXYMETAZOLINE COMPOSITIONS	RVL PHARMACEUTICALS, INC.
16/716,014	12/16/19	COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS	RVL PHARMACEUTICALS, INC.

Reel/Frame 55015/0762

Patent No. Publication Date Application No.	Issue Date Pub. Date App. Date	Title	Owner
17/064,915	10/7/20	Oxymetazoline compositions	RVL Pharmaceuticals, Inc.
17/063,416	10/5/20	Compositions and methods for treating ocular disorders	RVL Pharmaceuticals, Inc.

Reel/Frame 56724/0588

APPLICATION NUMBER	TITLE
17154676	Oxymetazoline Compositions
17194559	Compositions and methods for treating ocular disorders
62/843,819	COMPOSITIONS AND METHODS FOR TREATING BLEPHAROPTOSIS
62/844,069	COMPOSITIONS AND METHODS FOR TREATING BLEPHAROPTOSIS